Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Spero Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 44
- +6 vs. Q1 2025
- Shares held
- 11.1M
- −4.03M (−26.7%) vs. Q1 2025
- Total value
- $32.1M
- +$21.3M (+195.4%) vs. Q1 2025
- New holders
- 16
- 9 more added
- Sold out
- 10
- 9 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SPRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $47.5M |
| Q1 2026 | 50 | $48.3M |
| Q4 2025 | 56 | $49.2M |
| Q3 2025 | 47 | $21.3M |
| Q2 2025 | 44 | $32.1M |
| Q1 2025 | 38 | $10.9M |
| Q4 2024 | 50 | $16.1M |
| Q3 2024 | 46 | $16.5M |
| Q2 2024 | 48 | $18.0M |
| Q1 2024 | 54 | $23.7M |
| Q4 2023 | 50 | $19.6M |
| Q3 2023 | 54 | $17.2M |
| Q2 2023 | 56 | $20.8M |
| Q1 2023 | 48 | $20.6M |
| Q4 2022 | 60 | $24.6M |
| Q3 2022 | 69 | $39.7M |
| Q2 2022 | 79 | $15.5M |
| Q1 2022 | 100 | $176.1M |
| Q4 2021 | 84 | $316.7M |
| Q3 2021 | 88 | $338.3M |
| Q2 2021 | 89 | $244.2M |
| Q1 2021 | 95 | $273.1M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Spero Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 40 | $116 | 0.00% | +28+233.3% | Added |
| SBI Securities Co., Ltd. | 62 | $180 | 0.00% | +2+3.3% | Added |
| GWM Advisors LLC | 100 | $290 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 151 | $438 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 200 | $580 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 236 | $684 | 0.00% | −60,581−99.6% | Reduced |
| Advisor Group Holdings, Inc. | 290 | $841 | 0.00% | +290 | New |
| Tower Research Capital LLC (TRC) | 603 | $1.75K | 0.00% | +603 | New |
| Cullen/Frost Bankers, Inc. | 2,000 | $5.80K | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 3,082 | $8.94K | 0.00% | +3,082 | New |
| Bank of America Corp | 5,633 | $16.3K | 0.00% | +68+1.2% | Added |
| Royal Bank of Canada | 5,739 | $17.0K | 0.00% | +5,739 | New |
| UBS Group AG | 8,194 | $23.8K | 0.00% | +5,368+190.0% | Added |
| Group One Trading, L.P. | 8,239 | $23.9K | 0.00% | +8,239 | New |
| Morgan Stanley | 9,221 | $26.7K | 0.00% | +2,250+32.3% | Added |
| Texas Yale Capital Corp. | 10,000 | $29.0K | 0.00% | 00.0% | Unchanged |
| Invesco Ltd. | 14,968 | $43.4K | 0.00% | +14,968 | New |
| Cubist Systematic Strategies, LLC | 27,140 | $78.7K | 0.00% | +27,140 | New |
| Charles Schwab Investment Management Inc | 28,565 | $82.8K | 0.00% | 00.0% | Unchanged |
| Three Seasons Wealth, LLC | 30,000 | $87.0K | 0.01% | 00.0% | Unchanged |
| Simplex Trading, LLC | 30,322 | $87.0K | 0.00% | +25,224+494.8% | Added |
| Quadrature Capital Ltd | 31,205 | $90.5K | 0.00% | +31,205 | New |
| Capital Asset Advisory Services LLC | 32,548 | $94.4K | 0.00% | +32,548 | New |
| Axxcess Wealth Management, LLC | 32,548 | $94.4K | 0.00% | +32,548 | New |
| XTX Topco Ltd | 34,551 | $100.2K | 0.00% | +34,551 | New |
| Susquehanna International Group, LLP | 69,814 | $202.5K | 0.00% | +69,814 | New |
| Northern Trust Corp | 100,831 | $292.4K | 0.00% | −93−0.1% | Reduced |
| Citadel Advisors LLC | 103,786 | $301.0K | 0.00% | +42,470+69.3% | Added |
| Acadian Asset Management LLC | 112,889 | $327.0K | 0.00% | −758,323−87.0% | Reduced |
| Bridgeway Capital Management, LLC | 114,800 | $332.9K | 0.01% | −40,000−25.8% | Reduced |
| ADAR1 Capital Management, LLC | 143,917 | $417.4K | 0.07% | −657,360−82.0% | Reduced |
| Ionic Capital Management LLC | 150,000 | $435.0K | 0.49% | +150,000 | New |
| State Street Corp | 153,451 | $445.0K | 0.00% | +4,540+3.0% | Added |
| Stonepine Capital Management, LLC | 156,888 | $455.0K | 0.45% | +156,888 | New |
| EAM Investors, LLC | 239,140 | $693.5K | 0.11% | +239,140 | New |
| Monimus Capital Management, LP | 310,908 | $901.6K | 0.72% | 00.0% | Unchanged |
| BlackRock, Inc. | 434,768 | $1.26M | 0.00% | −47,314−9.8% | Reduced |
| Geode Capital Management, LLC | 510,699 | $1.48M | 0.00% | −14,170−2.7% | Reduced |
| Schonfeld Strategic Advisors LLC | 510,834 | $1.48M | 0.01% | +510,834 | New |
| Renaissance Technologies LLC | 832,165 | $2.41M | 0.00% | −138,742−14.3% | Reduced |
| Alphabet Inc. | 889,979 | $2.58M | 0.12% | 00.0% | Unchanged |
| Anson Funds Management LP | 1,615,469 | $4.68M | 0.86% | −2,183,463−57.5% | Reduced |
| Vanguard Group Inc | 1,950,381 | $5.66M | 0.00% | +186,761+10.6% | Added |
| Pfizer Inc | 2,362,348 | $6.85M | 1.19% | 00.0% | Unchanged |
| Murchinson Ltd. | 0 | $0 | 0.00% | −873,910−100.0% | Sold out |
| Atlas Venture Life Science Advisors, LLC | 0 | $0 | 0.00% | −305,255−100.0% | Sold out |
| Mackenzie Financial Corp | 0 | $0 | 0.00% | −209,031−100.0% | Sold out |
| DAFNA Capital Management LLC | 0 | $0 | 0.00% | −125,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −92,939−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −56,000−100.0% | Sold out |
| DLK Investment Management, LLC | 0 | $0 | 0.00% | −29,825−100.0% | Sold out |
| EP Wealth Advisors, LLC | 0 | $0 | 0.00% | −16,500−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −5,056−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |